London, UK, 26 SEPTEMBER 2024
30T is pleased to announce the successful completion of the interim analysis for Stage 1 of the Phase 2 trial evaluating RESP301 in the treatment of tuberculosis (RESP30X-EBA). The Trial steering committee convened on 13th August 2024 to conduct a comprehensive review of all safety and efficacy data, resulting in a unanimous decision to progress to Stage 2. The next phase will evaluate the safety and efficacy of RESP301 in combination with the standard of care HRZE regimen in tuberculosis patients.
Dr Syed Jafri; Chief Medical Officer, 30 Technology, stated:
“This marks an incredibly significant milestone for 30T, and we are excited to continue our collaboration with Prof Diacon and his team at TASK as we advance the development of our novel NO generating technology. Advancing into the next stage, we are eager to explore the potential of combining RESP301 with HRZE to improve treatment outcomes for tuberculosis patients”